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ED	 8.5	(508)	 15.6	(200)	 6.6	(308)	
Depression	 11.8	(701)	 16.4	(211)	 10.5	(490)	
Diabetes	mellitus	 13.2	(786)	 17.8	(228)	 11.9	(558)	
Dyslipidemia	 25.2	(1502)	 33.3	(427)	 23.0	(1075)	
Hypertension	 33.1	(1969)		 44.9	(576)	 29.8	(1393)	
Alcohol	abuse	 5.6	(333)	 4.8	(62)	 5.8	(271)	
Obesity	 6.2	(372)	 7.1	(91)	 6.0	(281)	
Smoking	 17.9	(1066)		 18.4	(236)	 17.8	(830)	
Sleep	disorder	 14.0	(835)	 21.6	(277)	 11.9	(558)	
UTI	 13.2	(789)	 30.7	(394)	 8.5	(395)	
Heart	failure	 6.2	(371)	 10.2	(131)	 5.1	(240)	
LUTS	medication	 9.2	(546)	 39.4	(506)	 0.9	(40)		
Antihypertensive	medication	 42.2	(2514)	 57.6	(740)	 38.0	(1774)	
Lipid	lowering	medication	 25.1	(1493)	 32.9	(423)	 22.9	(1070)	
Erectile	dysfunction	medication	 7.4	(440)	 13.2	(170)	 5.8	(270)	
Diabetes	medication	 10.0	(598)	 12.6	(162)		 9.3	(436)	
Cardiaca	 12.1	(719)	 19.4	(249)	 10.1	(470)	
Antidepressants	 14.4	(856)	 20.0	(257)	 12.8	(599)	
Anxiolytics	 27.9	(1660)	 37.7	(484)	 35.3	(1176)	
Antipsychotic	medication	 5.0	(297)	 6.5	(83)	 4.6	(214)	
ED:	Erectile	Dysfunction	,	UTI:	Urinary	tract	infection	
 
 
 
The	mean	age	was	70.5±12	years	in	the	LUTS	group	and	65.3±11.4	years	in	the	
population	without	LUTS.	In	the	LUTS	population	34.5%	was	>74	years	and	in	the	
population	without	LUTS	this	was	17.8%.		Erectile	dysfunction	was	present	in	16%	of	
the	LUTS	group	and	in	7%	of	the	No‐LUTS	group	(Table	3).		
Table	3	describes	the	characteristics	of	the	study	population.	Participants	with	LUTS	
were	more	frequently	diagnosed	with	hypertension,	dyslipidaemia,	heart	failure,	
diabetes	mellitus,	and	sleep	disorders	(all:	p<0.001).	Alcohol	abuse,	smoking,	and	
obesity	are	not	significant	associated	with	LUTS.		
All	investigated	groups	of	medication	were	significantly	used	more	frequently	in	the	
LUTS	group	than	in	the	no‐LUTS	group	(Table	3).	More	than	50%	of	men	with	LUTS	use	
antihypertensive	medication.	More	than	one	third	of	the	LUTS	population	use	lipid	
lowering	medication,	LUTS	medication,	and	anxiolytics.	Men	with	ED	registered	often	
use	medication	for	this	condition:	78%	(n=397)	medication	vs.	22	%	no	medication	
(n=111);	p<0.001.				
Survival	analysis		
Men	with	ED	registered	before	or	at	the	first	observation	of	LUTS	(n=	91)	were	excluded	
from	the	longitudinal	analysis.	There	is	a	significant	unadjusted	univariate	relationship	
between	LUTS	and	ED	(HR	0.65,	95%CI:	0.54‐0.78;	p<0.001).	The	hazard	ratio	of	LUTS	
for	ED,	in	the	adjusted	regression	model,	was	significant	but	reversed	(HR	1.41,	95%CI:	
1.12‐1.74;	p=0.002).	Therefore,	men	with	LUTS	were	more	likely	to	develop	ED,	at	any	
time,	than	men	without	LUTS.	LUTS	medication	was	found	to	confound	the	relationship	
between	LUTS	and	ED.		
Discussion	
To	the	best	of	our	knowledge	this	is	the	first	study	that	has	been	conducted	to	establish	
the	relationship	between	LUTS	and	ED	in	a	primary	care	population.	This	study	suggests	
the	presence	of	a	time	dependent	relationship	between	LUTS	and	ED.	Nowadays,	when	a	
patient	consults	his	general	practitioner	for	LUTS,	the	Dutch	guideline	LUTS	8	
recommends	to	inquire	about	the	presence	of	ED.	This	study	supports	this	
recommendation,	and	suggests	a	possible	causal	relation.			
Based	on	the	results	from	our	survival	analyses,	LUTS	is	related	to	ED.	It	supports	the	
results	found	in	the	few	longitudinal	cohort	studies.	12–14	We	found	that	only	the	use	of	
medication	for	LUTS	(a1	receptor	blockers,	or	5a	reductase	inhibitors)	confounded	the	
relationship	between	LUTS	and	ED.	Before	adjustment	there	is	a	35%	decreased	change	
 
 
 
of	ED,	after	adjustment	there	is	a	41%	higher	change	of	ED	in	men	with	LUTS.	This	effect	
of	LUTS‐medication	on	the	relationship	between	LUTS	and	ED	is	also	reported	in	earlier	
studies.	Results	are,	however,	conflicting.	25,26	Two	mechanisms	have	been	proposed	to	
explain	patients’	improved	sexual	functioning	after	treatment	for	LUTS	with	a‐blockers.	
First,	as	the	symptoms	become	less	bothersome,	patients	may	feel	less	‘disabled’	by	their	
urinary	symptoms	and	may	thus	be	better	able	to	enjoy	other	facets	of	life	without	
feeling	inhibited	or	limited.	Alternatively,	inhibition	of	the	a1‐	and	a1D‐adrenoceptor	
subtypes	that	predominate	in	cavernosal	smooth	muscle	should	facilitate	erection.	27		
No	other	longitudinal	studies	reported	the	effect	of	LUTS	medication	on	their	results.	12–
14	The	relationship	between	LUTS	and	ED	in	our	study	could	not	be	accounted	for	by	
COPD,	hypertension,	diabetes	mellitus,	obesity,	dyslipidaemia,	depression,	smoking,	
heart	disease,	and	medication.	However,	we	did	not	control	for	other	possible	
confounders,	such	as:	body	mass	index,	physical	activity,	use	of	alcohol,	diet,	or	surgical	
treatment	for	LUTS,	because	this	information	was	not	available	in	our	data.		
Despite	similar	conclusions,	it	is	difficult	to	compare	our	study	results	with	those	in	
other	studies,	because	study	populations	differ:	studies	were	performed	in	a	Chinese‐	14,	
Brazilian‐	12,	and	American	populations.13	Open	populations	or	a	selected	population	of	
health	care	professionals.13	LUTS	has	not	been	categorized	consistently	among	studies,	
different	cut‐off	points	were	used,	and	results	are	presented	in	either	OR,	HR	or	RR.	
Moreira	et	al12	did	not	present	results	from	the	IPSS	scores	of	174	men	from	their	study,	
earlier	described	in	their	study	methods.28	Instead	they	presented	men	with	BPH	(n	=	
15)	in	the	final	predictive	model	for	ED.		
There	are	several	explanations	for	the	relationship	between	LUTS	and	ED,	and	its	
pathophysiology.	For	example,	both	LUTS	and	ED	share	similar	risk	factors	that	include	
age,	medical	conditions	such	as	diabetes,	hypertension,	and	depression.	13,29	In	terms	of	
common	pathophysiology,	several	hypotheses	have	been	proposed	to	provide	possible	
biological	explanations	for	the	observed	association.	These	included:	(i)	Reduced	
production	of	nitric	oxide	synthase/nitric	oxide	in	the	pelvis	as	the	pathophysiological	
mechanism	that	was	responsible	for	both	ED	and	LUTS	30;	(ii)	Pelvic	atherosclerosis	
which	results	in	diffuse	atherosclerosis	of	prostate,	penis	and	bladder	that	impacts	both	
LUTS	and	ED	30;	and	(iii)	“Alternate	Pathways”	of	smooth	muscle	relaxation	and	
contraction	that	may	be	responsible	for	the	association	between	bladder	outlet	
obstruction	and	ED.31	Also,	it	is		suggested	that	the	psychological	impact	of	LUTS	could	
cause	ED	30	It	is	suggested	that	ED	in	men	with	LUTS		is	strongly	associated	with	both	
the	severity	of	LUTS	symptoms	and	the	degree	of	experienced	bothersomeness.	The	
 
 
 
authors	emphasize	the	potential	of	psychological	mechanisms	of	ED.	They	show	that		
urinary	bothersomeness	of	mild	LUTS	account	for	the	risk	of	ED	more	strongly	than	mild	
LUTS	themselves.29		
Strengths	of	this	study	include	a	large	primary	care	based	sample	across	a	wide	age	
range	(50‐91	years	old)	and	the	extended	follow‐up	time	(median	6.63	years(range	1‐14	
years),	compared	to	2‐5	years	in	previous	longitudinal	studies.	12,13,32	The	prevalence	of	
LUTS	in	this	study	is	comparable	to	the	prevalence	in	the	(open)	Dutch	population15,33,	
although	it	is	likely	that	LUTS	is	underreported	because	it	is	known	that	not	all	patients	
who	suffer	from	LUTS	consult	the	GP	for	this	reason.	34	The	data	collected	within	RNG	
are	extensive,	enabling	to	examine	many	potential	predictors	for	LUTS	and	ED.	The	RNG	
study	population	is	representative	of	the	Dutch	population.	35		The	RNG	supports	the	
need	for	qualitatively	good	data.	36	It	is	important	to	collect	data	complete	and	correct,	
to	code	all	episodes	of	care	with	ICPC	codes.	There	should	not	be	bulk	episodes,	
individual	complaints	or	disorders	are	recorded	under	different	episodes	of	care.	So,	all	
reported	LUTS	and	ED	is	recorded	with	ICPC	codes.		
Another	strength	of	this	study	is	the	possibility	to	correct	for	the	use	of	medication	in	
the	analysis	since	treatment	for	LUTS	may	affect	ED	outcome,	as	we	showed	in	our	
results.	
This	study	was	carried	out	based	on	a	primary	care	population	in	the	north‐eastern	part	
of	Netherlands.	Most	studies	describe	LUTS	patients	in	a	secondary	care	or	in	a	
community	setting,	using	the	IPSS	questionnaire	and	defining	a	score	>8	as	having	LUTS.	
We	defined	LUTS	as	having	consulted	the	GP	for	at	least	one	voiding	symptom,	as	LUTS	
is	not	covered	by	the	ICPC	coding	system.	We	cannot	differentiate	between	mild,	
moderate	or	severe	symptoms.	As	a	consequence,	comparing	our	results	with	those	of	
other	studies	is	problematic.	Also,	we	were	unable	to	differentiate	between	storage‐	and	
voiding	symptoms.	
For	the	lifestyle	factors,	such	as	smoking,	underreport	is	very	likely.	Probably,	smoking	
is	only	registered	as	ICPC	code	P17	in	case	of	the	intention	to	quit	smoking.	When	
compared	to	the	prevalence	of	smoking	in	the	Dutch	population	(23%)	we	would	expect	
a	higher	rate	of	smoking	men	≥50	years	than	the	observed	236	(4%)	within	the	LUTS	
population,	because	not	all	smokers	have	the	intention	to	quit	smoking,	let	alone	with	
the	help	of	GPs	or	practice	nurses.	For	future	research	it	would	be	better	to	improve	the	
registration	of	lifestyle	factors.	
 
 
 
We	were	not	able	to	include	all	cardiovascular	problems	in	our	analysis.	This	may	have	
biased	the	results	of	our	study.		It	is	still	questionable	if	the	relationship	between	LUTS	
and	ED	is	causal.	Not	many	studies	have	established	longitudinal	or	survival	analysis.	
Possibly,	this	relationship	may	depend	on	other	confounding	factors	than	considered	in	
our	data.	However,	despite	differences	in	study	methods,	populations,	definitions	of	
study	variables,	etc.	all	longitudinal	studies	reported	a	positive	relationship	between	
LUTS	and	ED.	Future	prospective	longitudinal	cohort	studies	may	further	clarify	this	
possible	causal	relationship,	and	its	pathophysiological	mechanisms.	More	prospective	
data,	as	well	as	more	standardised	methods,	including	registration	of	life	style	factors	as	
possible	confounders,	will	need	to	be	also	considered.			
Conclusion	
Our	results	suggest	that	lower	urinary	tract	symptoms	and	erectile	dysfunction	are	time‐
related.	For	the	general	practitioner	it	is	worthwhile	to	inquire	about	ED	symptoms	in	
men	with	LUTS	and	to	be	aware	that	men	with	LUTS	are	more	likely	to	have	ED	in	the	
future.			
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